A Post Marketing Surveillance (PMS) Study for VPRIV (Velaglucerase Alfa) in India
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Velaglucerase alfa (Primary)
- Indications Gaucher's disease
- Focus Adverse reactions
- Sponsors Shire
- 06 Jun 2023 Status changed from active, no longer recruiting to completed.
- 17 Jan 2023 Planned number of patients changed from 35 to 21.
- 17 Jan 2023 Planned End Date changed from 31 Mar 2023 to 26 Apr 2023.